HRH4 and atopic eczema: Several of the most promising H4R ligands entered into clinical trials, e.g., JNJ-39758979 (atopic dermatitis; trials terminated due to agranulocytosis [40], toreforant (rheumatoid arthritis; trials terminated due to lack of efficacy [40], or adriforant (atopic dermatitis; discontinued [39]).